Download Files:
Products Details
Product Description
– Cavrotolimod is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications.
Web ID
– HY-139785
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C300H423N71O161P26S23
References
– [1]Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. Front Immunol. 2022;13:1073777.|[2]Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front Med (Lausanne). 2023;9:959289.
CAS Number
– 2378664-12-9
Molecular Weight
– 9142.88
SMILES
– [Cavrotolimod]
Clinical Information
– Phase 2
Research Area
– Others
Solubility
– 10 mM in H2O
Target
– Toll-like Receptor (TLR)
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
